STARgraft Vascular Graft
Vascular Access for Hemodialysis in End-Stage Renal Disease (ESRD)
Key Facts
About Healionics
Healionics is a private, clinical-stage medical device company pioneering a novel synthetic biomaterial platform called STAR (Sphere Templated Angiogenic Regeneration). Its lead product, the STARgraft vascular graft, is designed to address the critical unmet needs of infection and occlusion in dialysis access, having received FDA Breakthrough Device designation based on promising human study data. The company leverages its deep roots in Seattle's dialysis innovation ecosystem to advance a solution that could significantly improve patient outcomes and reduce the high cost of dialysis care. Healionics appears to be in a late-stage development phase, positioning its lead graft for potential regulatory submission and commercialization.
View full company profile